Physician profile
Helen Ede
NPI 1265536759
$7,899.86
in general payments reported to CMS, 2019-2025
34 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $330 · 2021: $798 · 2022: $713 · 2023: $2,165 · 2024: $1,792 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,711 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,711.02 |
| Education | $146.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,237.18 | 2021-2025 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $913.78 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $895.32 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $619.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $537.93 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $471.66 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Vanda Pharmaceuticals INC. | $355.70 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $308.19 | 2023-2025 | Rexulti |
| Allergan, INC. | $184.84 | 2019-2020 | |
| Eisai INC. | $159.03 | 2020-2025 | |
| Pfizer INC. | $137.96 | 2019-2025 | |
| Amgen INC. | $134.91 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $126.02 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.00 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $107.65 | 2022-2024 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.92 | 2022-2025 | Steglatro, Segluromet, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $65.76 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $54.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.77 | 2022 | |
| Shield Therapeutics INC | $41.85 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $39.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.27 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.63 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $26.99 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.43 | 2025 | Gvoke Hypopen |
| Kaleo, INC. | $20.97 | 2023 | Auvi-Q |
| Almatica Pharma LLC | $19.93 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.28 | 2023 | Unithroid |
| Phathom Pharmaceuticals, INC. | $17.14 | 2024 | Voquezna |
| Medtronic, INC. | $15.61 | 2022 | |
| Ibsa Pharma INC. | $15.30 | 2023 | Tirosint, Licart |
| Nabriva Therapeutics, Plc | $12.54 | 2022 | |
| Shire North American Group INC | $12.22 | 2019 | |
| Horizon Therapeutics Plc | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Ede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.